Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn

Pediatrics

Volumn 131, Issue 1, 2013, Pages 79-87

  Van Marter, Linda J ^a,b,c   Hernandez Diaz, Sonia ^d   Werler, Martha M ^e,f   Louik, Carol ^e,f   Mitchell, Allen A ^e,f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON UNIVERSITY   (United States)

^f BOSTON UNIVERSITY   (United States)

Author keywords

Epidemiology; Newborn infant; Nonsteroidal antiinflammatory drugs; Perinatal health; Persistent fetal circulation; Pulmonary hypertension

Indexed keywords

IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALICYLIC ACID;

ARTICLE; ARTIFICIAL VENTILATION; ASPHYXIA; BLOOD VESSEL REACTIVITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SURVEILLANCE; DRUG EXPOSURE; ECHOCARDIOGRAPHY; EPIDEMIOLOGICAL DATA; ETHNICITY; FEMALE; GESTATIONAL AGE; HEMODYNAMICS; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MECONIUM ASPIRATION; MEDICAL RECORD; OXYGEN SATURATION; PERSISTENT PULMONARY HYPERTENSION; PRENATAL PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; THIRD TRIMESTER PREGNANCY; TRANSIENT TACHYPNEA OF THE NEWBORN; VERTICAL TRANSMISSION;

EID: 84872836939     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0496     Document Type: Article

References (44)

1. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: Focus on PPHN. Semin Perinatol. 2005;29(1):8-14
2. Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child. 1984;138 (6):592-595
3. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: Practice variation and outcomes. Pediatrics. 2000;105(1 pt 1):14-20
4. Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl. 1999;18:201-204
5. Gersony WM, Duc GV, Sinclair JC. "PFC" syndrome: Persistence of the fetal circulation. Circulation. 1969;40:111
6. Walsh-Sukys MC. Persistent pulmonary hypertension of the newborn. The black box revisited. Clin Perinatol. 1993;20(1):127-143
7. Clark RH, Huckaby JL, Kueser TJ, et al Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol. 2003;23(4):300-303
8. Glass P, Wagner AE, Papero PH, et al. Neurodevelopmental status at age five years of neonates treated with extracorporeal membrane oxygenation. J Pediatr. 1995;127 (3):447-457
9. Levin DL, Mills LJ, Weinberg AG. Hemodynamic, pulmonary vascular, and myocardial abnormalities secondary to pharmacologic constriction of the fetal ductus arteriosus. A possible mechanism for persistent pulmonary hypertension and transient tricuspid insufficiency in the newborn infant. Circulation. 1979;60(2): 360-364
10. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2005;39(6):492-503
11. Van Marter LJ, Leviton A, Allred EN, et al. Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics. 1996;97(5):658-663
12. Reece EA, Moya F, Yazigi R, Holford T, Duncan C, Ehrenkranz RA. Persistent pulmonary hypertension: Assessment of perinatal risk factors. Obstet Gynecol. 1987;70 (5):696-700
13. Bearer C, Emerson RK, O'Riordan MA, Roitman E, Shackleton C. Maternal tobacco smoke exposure and persistent pulmonary hypertension of the newborn. Environ Health Perspect. 1997;105(2):202-206
14. Murphy JD, Rabinovitch M, Goldstein JD, Reid LM. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr. 1981;98(6):962-967
15. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976;295 (10):530-533
16. Levin DL, Mills LJ, Parkey M, Garriott J, Campbell W. Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe. J Pediatr. 1979;94(4):647-650
17. Moise KJ Jr, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med. 1988;319(6):327-331
18. Eronen M, Pesonen E, Kurki T, Ylikorkala O, Hallman M. The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: A randomized doubleblind study. Am J Obstet Gynecol. 1991;164 (1 pt 1):141-146
19. Manchester D, Margolis HS, Sheldon RE. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol. 1976;126(4):467-469
20. Csaba IF, Sulyok E, Ertl T. Relationship of maternal treatment with indomethacin to persistence of fetal circulation syndrome. J Pediatr. 1978;92(3):484
21. Goudie BM, Dossetor JF. Effect on the fetus of indomethacin given to suppress labour. Lancet. 1979;2(8153):1187-1188
22. Rubaltelli FF, Chiozza ML, Zanardo V, Cantarutti F. Effect on neonate of maternal treatment with indomethacin. J Pediatr. 1979;94(1):161
23. Besinger RE, Niebyl JR, Keyes WG, Johnson TR. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol. 1991;164(4):981-986, discussion 986-988
24. Wilkinson AR, Aynsley-Green A, Mitchell MD. Persistent pulmonary hypertension and abnormal prostaglandin E levels in preterm infants after maternal treatment with naproxen. Arch Dis Child. 1979;54(12):942-945
25. Turner GR, Levin DL. Prostaglandin synthesis inhibition in persistent pulmonary hypertension of the newborn. Clin Perinatol. 1984;11(3):581-589
26. Norton ME, Merrill J, Cooper BA, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med. 1993;329(22): 1602-1607
27. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. 2001; 107(3):519-523
28. Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA. 1981;245(22):2311-2314
29. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007;120(2). Available at: Www.pediatrics.org/cgi/content/full/113/ 2/e87/120/2/e272
30. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587
31. Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol. 1986; 123(4):670-676
32. Harker LC, Kirkpatrick SE, Friedman WF, Bloor CM. Effects of indomethacin on fetal rat lungs: A possible cause of persistent fetal circulation (PFC). Pediatr Res. 1981;15 (2):147-151
33. Levin DL, Fixler DE, Morriss FC, Tyson J. Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr. 1978;92(3):478-483
34. Morin FC III. Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res. 1989;25(3):245-250
35. Clyman RI, Chen YQ, Chemtob S, et al. In utero remodeling of the fetal lamb ductus arteriosus: The role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death. Circulation. 2001; 103(13):1806-1812
36. Perkin RM, Levin DL, Clark R. Serum salicylate levels and right-to-left ductus shunts in newborn infants with persistent pulmonary hypertension. J Pediatr. 1980;96(4): 721-726
37. Levine EM, Ghai V, Barton JJ, Strom CM. Mode of delivery and risk of respiratory diseases in newborns. Obstet Gynecol. 2001;97(3):439-442
38. Jaillard S, Houfflin-Debarge V, Storme L. Higher risk of persistent pulmonary hypertension of the newborn after cesarean. J Perinat Med. 2003;31(6):538-539
39. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012
40. Soukka H, Rautanen M, Halkola L, Kero P, Kääpä P. Meconium aspiration induces ARDS-like pulmonary response in lungs of ten-week-old pigs. Pediatr Pulmonol. 1997; 23(3):205-211
41. Wu JM, Yeh TF, Wang JY, et al. The role of pulmonary inflammation in the development of pulmonary hypertension in newborn with meconium aspiration syndrome (MAS). Pediatr Pulmonol Suppl. 1999;18:205-208
42. van Ierland Y, de Beaufort AJ. Why does meconium cause meconium aspiration syndrome? Current concepts of MAS pathophysiology. Early Hum Dev. 2009;85(10): 617-620
43. Polglase GR, Hooper SB, Gill AW, et al. Intrauterine inflammation causes pulmonary hypertension and cardiovascular sequelae in preterm lambs. J Appl Physiol. 2010;108 (6):1757-1765
44. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: Pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8(8):443-455